The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 12)
Target Advancement Program, 2016
Loss-of-function GBA1 mutations in Gaucher disease result in increased risk for Parkinson's disease (PD). Glucocerebrosidase (GCase) normally breaks down a lipid called glucosylceramide (GluCer) that accumulates due to decreased GCase activity. Previous data have indicated that GluCer directly interacts with alpha-synuclein, the main component of Lewy body inclusions; the GluCer-al...
Researchers: Joseph R. Mazzulli, PhD
Research Grant, 2014
mGluR3 is a protein and target for neuroprotection. We have recently demonstrated that selective mGluR3 positive allosteric modulators (PAMs) mimic neuroprotective effects and production of neurotrophic factors (proteins that grow and protect neurons) induced by mGluR3 activation. The goals of the current project are to nominate an mGluR3 PAM candidate for pre-clini...
Researchers: Stephan Schann, PhD
Rapid Response Innovation Awards, 2012
Tools for early and unambiguous diagnosis of PD are currently missing and disease symptoms are easily mistaken. On the other hand, prompt recognition of PD subjects may increase the chances of therapeutic success. Our preliminary evidence that the level of a trace amine, octopamine, is altered in early PD provides new hopes for better diagnosis and therapy. Our aim is to inves...
MJFF Research Grant, 2012
Promising Outcomes of Original Grant:
Excessive amounts of amyloid in brain tissue are believed to be toxic and cause the neuronal damage that results in dementia. Amyloid deposits can be detected in life using brain scans with the agent PiB. Using PiB brain scans, we found that ~30% of non-demented PD patients have increased amyloid deposits, and that high PiB uptake was associated with declines...
Researchers: John Growdon, PhD
Alpha-synuclein Biology Challenge, 2012
Alpha-synuclein is a key protein involved in Parkinson's disease. Attempts have been made with drugs to lower the amount of this protein in the brain as a potential treatment for Parkinson's disease. However, neither the normal function of this protein nor the consequences of its reduction (e.g. by drugs) are well understood. We aim to investigate pre-clinic...